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Despite strong evidence of a social gradient in cancer survival among UK adults, studies in 
children and young people remain inconclusive and have not included renal tumours. This 
study investigated the relationship between socioeconomic status and survival from renal 
tumours among children and young people. 
Procedure. 
Kaplan-Meier estimation and Cox regression were used to analyse survival for all 209 renal 
tumours in children and young people (0-24 years) diagnosed 1968-2012 and registered by a 
specialist population-based registry. Sociodemographic and clinicopathologic variables, 
including paternal occupation at birth, were also analysed. 
Results. 
No significant disparity in overall renal tumour and Wilms tumour (WT) survival was observed 
according to paternal social class [p = 0.988 and 0.808, respectively]. The strongest predictor 
of survival was stage, with late stage (III-IV) disease having a 4-fold higher risk of death 
compared to early stage (I-II) disease [p < 0.001]. Similarly, high mortality-risk was seen for 
late stage WT in children aged 0-14 years (Hazard Ratio = 6.37; 95% CI = 2.60-15.59).  
Conclusions. 
This study did not detect a significant social gradient in renal tumour survival. The 
identification of tumour stage as a strong predictor of survival irrespective of age, necessitates 







Although survival has improved over the past four decades [1], cancer remains the leading 
cause of death for children (0-14 years) and young people (15-24 years) in the UK [2]. While 
rare in these age groups, renal tumours are an important heterogeneous group of cancers, 
representing 4-7% of new cases in children (0-14 years) and <1% of cases in young people 
(15-24 years) [3]. For several decades renal tumours have had one of the best prognostic 
outcomes among childhood cancers [3]. Population-based data from Europe and North 
America estimate 5-year survival to be > 85% for Wilms tumour (WT) and > 80% for all renal 
tumours [4,5]. Although 5-year survival from childhood renal tumours in the UK has improved 
over the past 40 years from 60% to 90% [6], with similar findings for northern England [7], 
survival rates continue to lag behind those of other European countries [4]. This puts childhood 
renal tumours at the forefront of the UK government’s National Cancer Strategy to identify 
modifiable prognostic factors for all childhood cancers [8]. Additionally, very few studies have 
attempted to estimate renal tumour survival in young people, and recent European data have 
shown that unlike childhood renal tumours, survival has not improved significantly in young 
people aged 15-24 years with renal tumours [9]. 
 
While studies have highlighted socioeconomic status (SES) as a strong predictor of survival 
from adult malignancies in developed countries including England [10,11,12], few studies have 
investigated the role of social deprivation in cancer survival among children and young people 
[13,14,15], with none examining renal tumours. An older study of fathers’ occupations had 
found an unexpected association between higher paternal social class and greater chance of the 




Northern England has persistently had poorer health than the rest of England and continues to 
experience a widening health gap [17]. Limited information is available regarding social 
determinants of cancer survival among children and young people resident in northern 
England. Findings from the few studies that have investigated this phenomenon have also 
tended to be contradictory. While studies using individual-level measures of SES have 
identified a significant association between social class and survival from childhood cancers 
such as leukaemia [13], those using area-level measures have been less consistent [14,18,19]. 
 
This study investigated whether survival from renal tumours in children and young people 
resident in northern England varied according to socioeconomic status as assessed by paternal 





The study population constituted all cases of malignant renal tumours in children (defined as 
ages 0-14 years) and young people (defined as aged 15-24 years), diagnosed 1968-2012 and 
registered on the Northern Region Young Persons’ Malignant Disease Registry (NRYPMDR). 
The registry’s study area covers the northern region of England and is located in the Newcastle 
upon Tyne Hospitals NHS Foundation Trust, a designated UKCCSG centre which also serves 
as the regional specialist centre for the treatment and management of adolescent cancers with 
a case ascertainment of 98% [20]. All cases are manually followed up through annual contact 
with responsible clinicians to determine patients’ current vital status and with GPs if patients 
have been discharged from long-term hospital clinics. This has resulted in < 1% of cases being 
lost to follow up [7]. Malignancies in the registry are grouped according to the International 
Classification of Childhood Cancers, Third edition (ICCC-3) [9]. 
 
Demographic information (age at diagnosis, gender) and details of diagnosis (year of diagnosis, 
tumour stage, histological subtype), are documented by the registry. Whenever possible, a copy 
of the birth certificate – which records paternal occupation  –  is also obtained. 
 
Paternal occupation – a reliable proxy measure of SES [13, 21] –  was coded using the revised 
1990 Standard Occupational Classification and used to assign paternal social class at the time 
of the study participant’s birth, classified as: I – Professional; II – Managerial; IIIN – Skilled 
non-manual; IIIM – Skilled manual; IV – Semi-skilled; V- unskilled. Class I was considered 
to be the most affluent and class V the most deprived. To enable ease of analysis and 
comparison with other similar studies, these social classes were collapsed into the following 3 
categories: Class I/II – Professional/Managerial; Class IIIN/M – Skilled non-manual/manual; 
Class IV/V – Semi-skilled/unskilled. A subset of study cases without documented paternal 
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occupation or for whom no appropriate social class could be coded was created. Renal tumours 
were classified according to histological subtype based on ICCC-3 and further collapsed into 
2 categories: Wilms Tumours (WT) and Non-Wilms renal tumours (NWRTs). Age at diagnosis 
was categorized as: 0-1, 2-4, 5-14 and 15-24 and year of diagnosis for all renal tumours was 
classified as 1968-1977, 1978-1987, 1988-1997, 1998-2007 and 2008-2012, with further 
analysis for WT cases according to clinical trial dates. The trial dates used for WT cases aged 
0-14 years were based on clinical trials open in the UK during our study period [22-27]. The 
trial periods followed were: 1968-1979 (MRC-1 and MRC-2 trials), 1980-2001 (UKW1, 
UKW2 and UKW3 were grouped together due to small numbers and overlapping dates), and 
2002-2012 (SIOP WT trial). Registry information on tumour stage is routinely obtained from  
histopathology reports and/or consultant notes and was categorized as early stage disease (stage 
I-II), late stage disease (stage III-IV), and bilateral disease for WT based on current 
SIOP/UKCCG staging criteria [3]. The most recent estimate for central re-examination of 
biopsy specimens is noted to be 78% [20]. 
 
Statistical Analysis 
All study covariates were treated as categorical variables, except age and year of diagnosis, 
which were also considered as continuous variables. Mann Whitney and Kruskal Wallis tests 
were used respectively to investigate the differences in median age at diagnosis between the 
sexes and across calendar periods, while Chi-square test was used to analyse associations 
between SES and covariates. Survival time was calculated as time in years from date of 
diagnosis to death from any cause or the last day of availability of survival information in the 
NRYPMDR. Study cases who were still alive were right censored from 31 December 2015. 
The Kaplan-Meier method was used to estimate one-, five- and ten-year survival rates 
according to the covariates and survival differences between groups tested via the log-rank 
8 
 
method. Hazard ratios (HRs) with 95% confidence intervals (CI) were obtained using the 
univariate Cox proportional hazards to assess effect of individual covariates on survival. 
 
Multivariate Cox regression was used to examine effect of social class on survival while 
controlling for potential confounding from demographic and clinicopathologic factors. Due to 
the relatively few cases of NWRTs, bilateral WT and young people (15-24 years) with renal 
malignancies within the study population, these parameters were excluded from the final Cox 
modelling and instead a subgroup survival analysis of all children (0-14 years) with WT was 
performed using multivariate Cox regression to adjust for relevant clinical and epidemiological  
covariates. Interactions were tested within the Cox regression framework. The likelihood ratio 
test was used in the assessment of nesting effects. A significance level of 0.05 was chosen for 
all tests. The Schoenfeld residuals were used to investigate the validity of the proportional 
hazards assumption for the Cox regression models and the global score test of proportional 
hazards based on the scaled Schoenfeld residual was used for all significant covariates. All 





Descriptive Characteristics of Study Population 
209 renal tumours were diagnosed during the study period. The sociodemographic and 
clinicopathologic characteristics of the study population are summarized in Table 1. Children 
with WT accounted for 78% of the study population and over 70% of cases were diagnosed 
before 5 years of age with children aged 2-4 years constituting the modal age group while less 
than 10% of tumours occurred in young people (Table 1).  Age at diagnosis ranged from 0-24 
years, with a median age of 3 years and interquartile range (IQR) of 5 years. There was no 
significant sex difference in age at diagnosis (p = 0.998).  
 
The study population consisted of 116 females and 93 males. While this sex distribution was 
maintained for children aged 0-14 years (male: female = 0.8), the proportion of males was 
slightly higher than females among young people aged 15-24 years (male:  female = 1.1). 
Information on paternal social class was available for 183 cases. The modal social class was 
IIIn/m and there was no association between SES and tumour stage (p = 0.502) or histological 
subtype (p = 0.958).  
 
WT was the most commonly diagnosed renal tumour (85% of cases) (Table 1). This was similar 
across all diagnostic periods, during which there was no significant change in the proportion 
of WT and NWRTs cases (p= 0.267). A higher proportion of WT and NWRTs cases were noted 
to present with early stage tumours than with late stage disease (53% vs 47% and 80% vs 20% 
respectively, p = 0.019). WT was mostly diagnosed before age 15 years – accounting for 162 
cases with a median age at diagnosis of 3 years (IQR= 3 years). Conversely, the majority of 
NWRTs were seen in young people (55% of cases) with a median age of 18 years (IQR = 19 
years). Overall, diagnosis with NWRTs was predominantly among males (male: female = 1.1), 
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becoming more noticeable in young people (male: female = 1.4). By contrast, children 
diagnosed with NWRTs or WT were mostly female (male: female = 0.8). Of the 209 study 
cases, 59 had died by the end of the follow up period (Table 1).   
 
Kaplan-Meier Survival Estimates and Univariate Cox Regression Analysis 
The crude survival rates and unadjusted hazard ratios (HR) on univariate analysis according to 
sociodemographic and clinicopathologic factors for all study cases are outlined in Table 2. 
Overall survival from renal tumours was 86% at 1-year after diagnosis, falling to approximately 
74% from 5-years onward. The median duration of survival for all study cases was 17 years 
(IQR = 26 years), being longer for WT cases (Median survival = 19 years; IQR = 25 years) 
than for NWRTs (median survival = 6 years; IQR = 16 years). 
 
There was no significant disparity in renal tumour survival according to paternal social class 
at birth (Figure 1). Survival rates remained similar for all social classes at all time points, with 
a 17-18% increased risk of mortality in the lower social classes compared to the most affluent 
socioeconomic group, although this was not found to be statistically significant (Table 2). 
Survival from early stage tumours and WT was consistently better across all social classes 
compared to late stage tumours and NWRTs respectively. 
 
Little difference was seen in survival among the three childhood age groups. In contrast, young 
people with renal tumours were found to have a significantly higher risk of dying compared to 
the youngest age group (crude HR = 4.43; 95% CI = 1.88, 10.45). The study period saw a 
progressive improvement in renal tumour survival except during the last 2 periods (1998-2007 
and 2008-2012) in which survival was slightly higher in 1998-2007 period compared to 2008-
2012 (Table 2), possibly due to shorter duration (with fewer cases) of the latter period. There 
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was substantial disparity in survival from renal malignancies depending on tumour stage at 
diagnosis (p < 0.001; Figure 2). Study cases with early stage tumours had a significantly higher 
survival rate than those with late stage and bilateral WT (Table 2). Diagnosis with late stage 
tumour carried a three-and-a-half-fold increased risk of death compared to early stage tumours 
(p < 0.001), while bilateral WT was associated with an approximately three-fold higher risk of 
dying compared to early stage tumours (p = 0.040). Similarly, survival was significantly worse 
for those diagnosed with NWRTs compared to WT, with the disparity becoming especially 
pronounced from 5-years post-diagnosis onward (Table 2). The risk of dying was twice as high 
for cases diagnosed with NWRTs compared to WT (p = 0.026).  
 
Subgroup Analysis – Multivariate Cox Modelling for Children (0-14 years) with WT 
Prior to multivariate Cox modelling, Kaplan-Meier survival estimation and univariate Cox 
regression were carried out for all childhood WT cases aged 0-14 years (Supplemental Table 
S1, Supplemental Table S2, Supplemental Table S3). No significant association was noted 
between paternal social class and other study covariates (Supplemental Table S2), while 
presentation with late stage WT was observed to increase with age (p = 0.001, Supplemental 
Table S2). Cox regression modelling showed trial period and tumour stage at diagnosis to be 
significant in the final model (Table 3) and did not abrogate the proportional hazards 
assumption (Global test χ2 = 4.00, df = 8; p = 0.857). Children with late stage WT had a six-
fold higher risk of dying compared to children with early stage disease and there was a 
significant reduction in mortality risk for patients treated during the latter trial periods 
compared to the MRC 1 and 2 trials which ran from 1968-1979 (Table 3). Marked improvement 
was observed in 5-year survival between the first and last calendar periods (i.e. 1968-1977 and 
2008-2012) from 65% to 94% (Supplemental Table S3). There was little to no variation in 
childhood WT survival according to paternal social class at birth (p = 0.808), and the most 
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deprived socioeconomic groups were not found to be at a significantly higher risk of dying 
compared to the more affluent, even after adjusting for significant covariates (Table 3). 
Interactions were considered but not included in the final model due to small case numbers and 
missing data particularly for tumour stage and SES. However, conducting a subgroup analysis 





This is the first population-based study to exclusively examine the role of SES in survival from 
malignant renal tumours in children and young people. We did not detect a significant 
socioeconomic disparity in renal tumour survival. Tumour stage, histological subtype and trial 
period were each found to be strong predictors of survival and young people had a significantly 
higher mortality risk compared to children. 
 
The availability of high quality data from the NRYPMDR, including birth certificates, ensures 
reliability of data on paternal occupation. Furthermore, paternal occupation as an individual-
level measure for SES has been shown to be a reliable and valid SES indicator associated with 
a lower risk of non-differential misclassification compared to area-level measures [28,29]. The 
availability of detailed clinical information also allows robust analysis of determinants of renal 
tumour survival. 
 
However, due to the relatively small sample size there was limited statistical power to estimate 
survival characteristics for young people with a high degree of precision and multivariate Cox 
regression could only be performed for childhood WT. While we were able to adjust our study 
findings for a number of important prognostic factors obtained from the registry, residual 
confounding from other factors such as treatment protocol, relapse rate(s), tumour volume and 
biomarkers – which were not available – may have led to an over- or under-estimation of 
survival outcomes. Chance and/or a lack of statistical power cannot be ruled out as possible 
explanations for some of our study results. The current staging criteria used by UKCCSG/SIOP 
for childhood renal tumours has also undergone some minor adjustments from earlier staging 
systems. One such important modification implemented after the MRC-2 trial was the 
upgrading of patients with regional lymph node involvement from stage II to stage III [30]. 
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While the new staging system was used in the registry from 1980 onwards, the older system 
would have been used during the period 1968-1979, and the stages on the registry would not 
have been updated. It is possible that some of the historical WT cases previously classified as 
stage II prior to 1980 have in fact been misclassified as early stage tumours for the purpose of 
this study. However, only a small proportion of WT cases diagnosed during the period 1968-
1979 were stage II (8/52 of all cases with known stage at diagnosis) and this misclassification 
effect can be considered negligible. The lack of registry information on fathers’ working 
conditions and level of autonomy meant that paternal occupation could not be classified using 
the updated NS-SEC occupational classification of SES, which is more salient than the SOC-
90 classification in reflecting socioeconomic positions of modern societies [31]. Furthermore, 
SES was based on paternal occupation at birth but not at a later time point such as time of 
diagnosis, thus introducing the risk of SES misclassification for some study cases if a change 
in occupation or paternal role since birth has resulted in a similar change in SES group. The 
singular use of paternal occupation as a SES proxy also fails to acknowledge the evolving 
landscape of family structures in the UK through the decades, which has seen the proportion 
of lone mother households rise from 6% to 22% over the past 30 years. Finally, it is possible 
that using only paternal occupation as an indicator for SES doesn’t fully encapsulate its 
multidimensional nature and other facets through which it might influence renal tumour 
survival.  
 
Despite these limitations, the absence of a significant social gradient in renal tumour survival 
in children and young people is consistent with findings from other population-based studies 
that have examined the role of SES in survival from various solid tumours in these age groups. 
Prior studies from the UK, Ireland and Sweden have shown no association between parental 
SES and central nervous system (CNS) tumour survival in children (0-14 years) using both 
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individual-level and area-level measures of SES [32,33,34]. Furthermore, a large UK study 
failed to identify a relationship between material deprivation and survival from most solid 
tumours in teenagers and young adults aged 13-24 years [35]. Nevertheless, others have 
reported a significant association between parental SES (measured by educational level) and 
survival from CNS tumours among children in Switzerland, as well as poorer survival with 
increasing deprivation for young people in England diagnosed with melanoma and carcinomas’ 
of head, neck and colon [15,36]. The inconsistent findings among such studies may be related 
to an interaction of underlying differences in cancer symptomatology, patient characteristics, 
social structures such as accessibility and availability of cancer care services, and the different 
SES indicators used.  
 
Cancer-specific symptoms may indirectly influence survival via tumour characteristics such as 
stage at diagnosis. Although a recent study showing that renal tumours in UK children are 
detected at a more advanced stage and with poorer outcome than in German children, a 
concurrent clinical audit of all WT cases presenting to three major UK paediatric oncology 
centres, including the Royal Victory Infirmary (RVI) in Newcastle, showed no evidence of a 
therapeutic delay once contact with a GP had been made, but rather a system of rapid access to 
diagnostic investigation and treatment [37]. This implies that the delay in tumour presentation 
and associated poorer survival among UK children may be linked to factors outside of the 
cancer care pathway such as issues related to parent recognition of signs/symptoms, or the 
failure of GPs to detect asymptomatic early stage tumours. While it has been suggested that 
delays in cancer diagnostic and referral pathways are more likely to occur in countries where 
general practitioners (GPs) act as gatekeepers to specialist care [38], a systematic review of 
diagnostic delay in childhood cancers found that renal tumours have a significantly shorter lag-
time between symptom recognition and diagnostic confirmation compared to all other 
16 
 
childhood cancers and children with shorter delays are more likely to present with certain 
cancer warning symptoms such as an abdominal mass, which has a higher probability of 
prompting urgent health-seeking actions by parents compared to other non-specific cancer 
symptoms e.g. weight loss and general malaise [39]. Additionally, a Mexican study found no 
substantial risk of a delayed diagnosis from childhood renal tumours regardless of parental SES 
[40] with similar findings also reported for abdominal tumours in adults [41]. Therefore, the 
lack of a significant social gradient in renal tumour survival in this study may be due to the 
absence of class differences in symptom recognition.  The observed predominance of early 
stage renal tumours in this study regardless of age and histological subtype also supports this 
hypothesis. It would be of interest to determine whether the survival disparity between the UK 
and other European countries is rather linked to population differences in renal tumour biology, 
such as a higher incidence of tumours with genetic mutations that reduce chemotherapy and 
radiotherapy response rates among UK children, or due to international differences in 
therapeutic management. 
 
Studies have shown that social gradient in cancer survival could be due to differences in type 
of treatments offered to patients from different social classes [42] including poorer treatment 
adherence among patients from lower social classes [43]. Evidence also suggests that when 
treatment is equal, such as in clinical trials or highly specialized clinics, social class differences 
in cancer survival disappear [44]. Since all UK children diagnosed with renal tumours have 
been systematically enrolled in the United Kingdom Children’s Cancer Study Group 
(UKCCSG) and International Society of Pediatric Oncology (SIOP) clinical trials, this could 
account for the absence of a socioeconomic variation in childhood renal tumour survival. This 
may not apply to young people (15-24 years) as they were excluded from these trials, universal 
access to health services free at the point of delivery via the National Health Service (NHS) in 
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the UK may be a contributing factor for the lack of a clear SES gradient in survival for this age 
group.  
 
Significantly poorer prognosis observed for young people aged 15-24 years is consistent with 
evidence that little has changed in renal tumour survival among teenagers and young adults in 
the UK and northern England [2,14]. A plausible biological basis for this survival disparity is 
that therapies administered to this age group are often derived from clinical trials conducted in 
younger children [35] and little translational research has been done to discover potential 
biological differences in cancers that occur in children versus young people, leading to worse 
prognosis for renal tumours with age increase [45]. Other explanations for the inverse 
relationship between survival and age at diagnosis may lie in the latter’s association with 
tumour stage at diagnosis and histological subtype. With risk of late stage disease observed to 
worsen with increasing age among children with WT, poorer prognosis seen among older age 
groups may be attributed to higher burden of advanced tumours.  Additionally, the majority of 
young people were diagnosed with NWRTs – a collection of renal neoplasms mostly known to 
have worse survival outcomes than WT and for which satisfactory treatment protocols are yet 
to be formulated [46]. 
 
Finally, it is acknowledged that no single indicator encapsulates the multidimensionality of 
SES and that certain indicators are likely to measure only part of its domains [21] and area-
level measures might dilute the exposure-outcome relationship as a result of aggregation. This 
is supported by studies that have shown a disappearance of survival disparities for both 
childhood and adult cancers when area-level measures of SES were used instead of individual-
level measures [35,47]. It is possible that contradictory reports of the relationship between SES 
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and cancer survival in children and young people are partly due to use of SES indicators that 
fail to capture both social structure(s) and psychosocial determinants of population health.  
 
In conclusion, this study found no significant social gradient in renal tumour survival among 
children and young people in northern England. The lack of SES disparities in survival 
combined with significant temporal improvement in renal tumour survival among children 
compared to poorer outcome for young people, may reflect systematic recruitment of children 
into clinical trials that use standardized risk-adapted therapies, suggesting that survival 
disparity between children and young people observed in our study may be due to differences 
in therapeutic process. The identification of tumour stage at diagnosis as a strong predictor of 
survival irrespective of age highlights importance of research to develop appropriate public 
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Figure 1 – Kaplan-Meier survival curves showing survival estimates by paternal social class 
for renal tumours in children and young people resident in northern England, 1968 – 2012. 
Figure 2 – Kaplan-Meier survival curves showing survival estimates by tumour stage at 
diagnosis for renal tumours in children and young people resident in northern England, 1968 
– 2012. 
Figure 3 – Kaplan-Meier survival curves showing survival estimates by Tumour stage at 
diagnosis for Wilms’ tumour in children (0-14 years) resident in northern England, 1968 – 
2012. 
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TABLE 1 – Sociodemographic and clinicopathologic characteristics of all cases of renal tumours in 
children and young people resident in northern England, 1968 – 2012. 
Variable N (% of Total) 
Age at diagnosis (years) 
0 - 1 
2 - 4 
5 - 14 




                 19 (9) 










1968 – 1977 
1978 – 1987  
1988 – 1997 
1998 – 2007 







Early stage tumour (stage I-II) 
Late stage tumour (stage III-IV) 








Non-Wilms renal tumours 










2 (1)  
20 (10) 
Survival status at end of follow up period  
Dead 
Survived 












TABLE 2 – One-, Five-, and Ten-year crude survival rates (95% confidence intervals) and crude hazard ratios 
with corresponding p-values according to sociodemographic and clinicopathological factors for renal 























87 (80 – 92) 
84 (75 – 90) 
75 (66 – 82) 
72 (62 – 80) 
75 (66 – 82) 
71 (60 – 79) 
1.00 
1.27 (0.76 – 2.12) 0.359 
Age at diagnosis (years) 
0 – 1  
2 – 4 
5 – 14 
15 – 24 
88 (76 – 94) 
87 (78 – 92) 
88 (74 – 95) 
68 (43 – 84) 
83 (70 – 90) 
77 (67 – 84) 
69 (53 – 81) 
42 (20 – 63) 
83 (70 – 90)   
75 (65 – 83) 
69 (53 – 81) 
 42 (20 – 63) 
1.00 
1.56 (0.75 – 3.26) 
1.98 (0.88 – 4.45) 









87 (75 – 94) 
84 (75 – 90) 
85 (70 – 93) 
74 (60 – 84) 
73 (62 – 81) 
75 (59 – 86) 
72 (58 – 82) 
73 (62 – 81) 
75 (59 – 86) 
 1.00 
 1.18 (0.60 – 2.30) 





1968 – 1977 
1978 – 1987 
1988 – 1997 
1998 – 2007 
2008 – 2012 
78 (65 – 87) 
78 (62 – 88) 
  86 (74 – 93) 
97 (82 – 100) 
  96 (74 – 99) 
63 (48 – 74) 
68 (52 – 80) 
71 (58 – 81) 
89 (74 – 96) 
88 (66 – 96) 
61 (46 – 73) 
68 (52 – 80) 
71 (58 – 81) 
89 (74 – 96) 
88 (66 – 96) 
           1.00 
0.89 (0.46 – 1.74) 
0.66 (0.34 – 1.28) 
0.23 (0.08 – 0.68) 







Early stage tumour (I-II) 
Late stage tumour (III-IV) 
Bilateral disease (V) 
91 (82 – 95) 
82 (71 – 89) 
71 (41 – 88) 
85 (76 – 91) 
56 (44 – 67) 
64 (34 – 83) 
84 (75 – 90) 
56 (44 – 67) 
64 (34 – 83) 
 1.00 
 3.47 (1.85 – 6.52) 






Non-Wilms renal tumour 
88 (83 – 92) 
71 (52 – 84) 
76 (69 – 82) 
58 (39 – 73) 
76 (69 – 81) 
58 (39 – 73) 
 1.00 




Abbreviations: n/a – not applicable  
                        CI – Confidence Interval      




TABLE 3 – Crude and adjusted hazard ratios (95% Confidence Interval) by demographic and 


















1.54 (0.82 – 2.89) 0.180 
1.00 
1.22 (0.78 – 2.85) 0.629 
Age at diagnosis  
0 – 1  
2 – 4 
5 – 14 
1.00 
1.57 (0.67 – 3.69) 





0.87 (0.48 – 2.28) 








  1.00 
1.20 (0.53 – 2.72) 





  1.12 (0.48 – 2.59) 




Tumour Stage  
Early stage (I-II) 





6.37 (2.60 - 15.59) 
<0.001 
Trial Period  
MRC 1 & 2 (1968-1979) 
UKW1-UKW3 (1980-2001) 








0.36 (0.17 - 0.78) 




Calendar Period  
1968 – 1977 
1978 – 1987 
1988 – 1997 
1198 – 2007 
2008 – 2012  
1.00 
0.69 (0.31 – 1.56) 
0.38 (0.16 – 0.92) 







–   – 
 
Abbreviations: n/a – not applicable  
                        CI – Confidence Interval      







FIGURE 1 – Kaplan-Meier survival curves showing survival estimates by paternal social class for renal 
tumours in children and young people resident in northern England, 1968 – 2012. 
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FIGURE 2 – Kaplan-Meier survival curves showing survival estimates by tumour stage at diagnosis for 
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FIGURE 3 – Kaplan-Meier survival curves showing survival estimates by Tumour stage at diagnosis for 
Wilms’ tumour in children (0-14 years) resident in northern England, 1968 – 2012. 
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SUPPLEMENTAL TABLE S1 – Sociodemographic and clinicopathologic characteristics of all cases of 




Variable N (% of Total) 
Age at diagnosis (years) 
0 - 1 
2 - 4 














1968 – 1977 
1978 – 1987  
1988 – 1997 
1998 – 2007 







Early stage tumour (I-II) 





Survival status at end of follow up period  
Dead 
Survived* 












SUPPLEMENTAL TABLE S2 – Sociodemographic characteristics by tumour stage of diagnosis and the 
relative risk of presenting with late stage disease for all cases of Wilms’ tumour in children (0-14 years) 






(% of n) 
Late stage 
tumour 












1.10 (0.77 – 1.59) 0.873
† 
Age at diagnosis (years) 
0 – 1  
2 – 4 
5 – 14 
 29 (78) 
33 (45) 





1.57 (1.20 – 2.04) 
2.31 (1.40 – 3.79) 
0.001‡ 











1.11 (0.80 – 1.55) 
1.23 (0.70 – 2.18) 
0.736† 
Keys:  n - number of cases per tumour stage category 
           † - Pearson’s χ2 test 
           ‡ -  χ2 test for trend 
NB: Cases with missing data not included  







SUPPLEMENTAL TABLE S3 – One-, Five-, and Ten-year crude survival rates (95% confidence intervals) 
according to sociodemographic and clinicopathological factors for Wilms’ tumour in children (0-14 years) 













93 (86 – 97) 
85 (75 – 92) 
81 (71 – 88) 
76 (64 – 84) 
81 (71 – 88) 
74 (63 – 83) 
Age at diagnosis (years) 
0 – 1  
2 – 4 
5 – 14 
88 (74 – 95) 
89 (90 – 94) 
92 (76 – 97) 
84 (64 – 92) 
79 (68 – 86) 
72 (54 – 84) 
84 (64 – 92) 
77 (67 – 85) 
72 (54 – 84) 




93 (80 – 98) 
90 (80 – 95) 
87 (69 – 95) 
84 (70 – 92) 
78 (66 – 86) 
77 (58 – 89) 
82 (67 – 90) 
78 (66 – 86) 
77 (58 – 89) 
Calendar period 
1968 – 1977 
1978 – 1987 
1988 – 1997 
1998 – 2007 
2008 – 2012 
80 (66 – 89) 
87 (69 – 95) 
93 (80 -98) 
96 (76 – 100) 
94 (65 – 99) 
65 (50 – 77) 
77 (58 – 89) 
84 (69 – 92) 
85 (64 – 94) 
94 (65 – 99) 
63 (48 – 75) 
77 (58 – 89) 
84 (69 – 92) 
85 (64 – 94) 
- 
Tumour stage 
Early stage tumour (I-II) 
Late stage tumour (III-IV) 
96 (88 – 99) 
81 (69 – 98) 
93 (85 – 97) 
57 (45 – 68) 
92 (83 – 96) 
57 (45 – 68) 
 
Abbreviations: n/a – not applicable  
                        CI – Confidence Interval      
                        WT – Wilms’ Tumour 
 
NB: Data represent survival rates in percentages (95% confidence interval) unless stated otherwise 
 
 
 
 
 
